NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity PAR-17-479 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support clinical trials for projects that were previously funded by NIH SBIR and STTR Phase II awards. The projects must focus on products related to the mission and goals of the National Institute of Neurological Disorders and Stroke (NINDS) and may evaluate drugs, biologics, devices, or diagnostics, as well as surgical, behavioral or rehabilitation therapies. Since conducting the clinical trials needed for commercialization may be capital-intensive, the FOA aims to facilitate the transition of SBIR Phase II projects to the commercialization stage by promoting partnerships between NIHs SBIR/STTR awardees and third-party investors and/or strategic partners. Consistent with the goals of this funding initiative and as required by the SF424 instructions for all SBIR Phase II applications, applicants must submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the project period. It is expected that the level of this independent third-party funding will equal or exceed the NINDS funds being requested throughout the SBIR Phase IIB project period.
Funding Opportunity PA-17-477 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) calls for research on the health of transgender and gender nonconforming people of all ages, including both youth and adults who are questioning their gender identity and those individuals who are making or who have made a transition from being identified as one gender to the other. This group encompasses individuals whose gender identity differs from the sex on their original birth certificate or whose gender expression varies significantly from what is traditionally associated with or typical for that sex.
Funding Opportunity PA-17-478 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) calls for research on the health of transgender and gender nonconforming people of all ages, including both youth and adults who are questioning their gender identity and those individuals who are making or who have made a transition from being identified as one gender to the other. This group encompasses individuals whose gender identity differs from the sex on their original birth certificate or whose gender expression varies significantly from what is traditionally associated with or typical for that sex.
Funding Opportunity PAR-17-475 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement is to support basic research examining how Electronic Nicotine Delivery Systems (ENDS) aerosols affect normal and disease states relevant to human cells, tissues and organs.
Funding Opportunity PAR-17-476 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement is to support basic research examining how Electronic Nicotine Delivery Systems (ENDS) aerosols affect normal and disease states relevant to human cells, tissues and organs.
Notice NOT-OD-17-109 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-NS-18-001 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage cooperative agreement (U54) applications from multidisciplinary groups of investigators to accelerate the rate of progress in determining the functional, pharmacological, neuronal network and whole animal consequences of genetic variants discovered in patients with various types of epilepsy and to develop strategies for establishing diagnostic criteria and identifying potential targets for intervention.
Funding Opportunity RFA-DK-17-015 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NIDDK R25 program is to support educational activities that enhance the diversity of the biomedical, behavioral and clinical research workforce. This R25 program encourages Professional Societies to design and implement educational programs with the goal of recruiting of individuals from underrepresented backgrounds to pursue careers in the biomedical, behavioral, clinical, and social sciences workforce. Applications from Professional Societies supporting the NIDDK mission areas are encouraged to develop educational programs aimed at recruiting talented , fellows, and junior faculty from groups underrepresented in biomedical, behavioral, clinical, and social sciences research in the NIDDK mission areas. Professional Societies should propose an educational program based upon an educational experiment which includes a diversity management plan for the Society which should enhance the diversity of the biomedical research workforce, and the pool of individuals from under represented groups in the organization's programs and leadership.
Funding Opportunity RFA-HS-17-012 from the NIH Guide for Grants and Contracts. The Agency for Healthcare Research and Quality (AHRQ), in partnership with the Patient-Centered Outcomes Research Institute (PCORI), invites applications for funding to support institutional career development awards designed to train clinician and research scientists to conduct PCOR research within learning health systems (LHS) focused on generation, adoption, and application of evidence in order to improve the quality and safety of care.
Notice NOT-TR-17-022 from the NIH Guide for Grants and Contracts
Notice NOT-HS-17-020 from the NIH Guide for Grants and Contracts
Notice NOT-AT-17-015 from the NIH Guide for Grants and Contracts
Organotypic Culture Models developed from Experimental Animals for Chemical Toxicity Screening (R43)
Funding Opportunity RFA-ES-17-008 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports Phase I (R43) and Fast Track (R44) Small Business Innovative Research (SBIR) grant proposals from small businesses concerns (SBCs) to develop novel, physiologically-relevant in vitro screening systems (e.g., engineered 3-dimensional or organotypic models) using cells derived from animal species typically utilized for toxicological testing, which will replicate biological interactions and toxicological responses observed in animal tissues or organs, will produce assay data suitable for comparisons between in vitro and in vivo animal toxicology studies, and may ultimately provide alternative methods to reduce the use of animals in toxicity testing. These systems will provide the improved understanding of biological processes and mechanisms of toxicity, and produce relevant data for alternative chemical exposure assessment methods to reduce animal testing.
Notice NOT-HL-17-538 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-CA-17-041 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to increase case ascertainment and optimize delivery of evidence-based healthcare for individuals at high risk of cancer due to an inherited genetic susceptibility. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP) Recommendation E: "To realize the potential of cancer prevention and early detection in our nation, NCI should sponsor an initiative to improve the current state of early detection, genetic testing, genetic counseling, and knowledge landscape of the mechanisms and biomarkers associated with cancer development. This initiative should include demonstration projects that will show how cancer screening programs can simultaneously save lives, improve quality of life, and reduce healthcare costs."
Funding Opportunity PAR-17-472 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement is to support studies on electronic nicotine delivery systems (ENDS) that examine population-based, clinical and applied prevention of disease, including etiology of use, epidemiology of use, potential risks, benefits and impacts on other tobacco use behavior among different populations.
Funding Opportunity PAR-17-473 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement is to support studies on electronic nicotine delivery systems (ENDS) that examine population-based, clinical and applied prevention of disease, including etiology of use, epidemiology of use, potential risks, benefits and impacts on other tobacco use behavior among different populations.
Funding Opportunity PAR-17-474 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to stimulate research on interventions to reduce HIV/AIDS-associated stigma and its impact on the prevention and treatment of HIV/AIDS and on the quality of life of People Living with HIV/AIDS (PLWH). Specifically, this initiative will support research on a) novel stigma reduction interventions that link to increase in care-seeking behavior and/or decrease in transmission; b) reducing the impact of stigma on adolescent and/or youth health; c) strategies to cope with the complex burden of stigmatization due to HIV and one or more comorbidities/coinfections; d) reducing effects of stigma on and/or by family members or caregivers of PLWH; and e) innovative and improved stigma measurement in the context of implementation of an intervention. The overall goals are to understand how to reduce stigma as a factor in HIV transmission, to eliminate or mitigate the aspects of stigma that limit beneficial health outcomes for the infected and at-risk individuals and communities, and to initiate exploratory studies to determine the feasibility of stigma interventions related to HIV prevention, treatment and/or care in Low and Middle-Income Countries (LMICs).
Notice NOT-CA-17-083 from the NIH Guide for Grants and Contracts
Notice NOT-CA-17-082 from the NIH Guide for Grants and Contracts